Almirall: share price climbs, results and forecasts hailed

(CercleFinance.com) - Almirall shares rose sharply on Monday morning on the Madrid Stock Exchange following the publication of better-than-expected annual results and the announcement of above-consensus forecasts for 2025.


The Spanish pharmaceutical company, which has a strong presence in dermatology, said this morning that it had exceeded its targets last year, with sales up 10.2% to E985.7m.

Ebitda rose by 10.6% to E192.6m.

The Barcelona-based group explains that it benefited from double-digit sales growth in its current main growth drivers.

Its treatment for atopic dermatitis (eczema) posted 34% growth in Q4 alone, to reach total annual sales of E33.2m euros in 2024, mainly in the German market.

Its Ilumetri plaque psoriasis drug, available in pre-filled syringes, also continued its growth trajectory, with sales up 25.5% to E208.8m, driven by market share gains.

For 2024, Almirall has set itself the target of increasing net sales by 10% to 13%, with Ebitda expected between E220m and E240m, again exceeding consensus estimates.

Listed on the Madrid Stock Exchange, the share price climbed 6.6% on Monday morning, returning to its highest level since last summer.


Copyright (c) 2025 CercleFinance.com. All rights reserved.